For example, semisynthetic Obeticholic acid is recognized as the most potent (FXR) agonist and is used as a drug to treat primary biliary cholangitis, and it is undergoing development for deployment in further liver diseases and related disorders2, such as nonalcoholic steatohepatitis (NASH). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.